This randomized trial compares the effects of induction gemcitabine with vs without erlotinib in patients with locally advanced pancreatic cancer and, among those responsive to treatment, compares the effects of chemotherapy with vs without radiation.
This randomized clinical trial compares the effect of sulindac and erlotinib vs placebo on duodenal adenoma regression among people with familial adenomatous polyposis.
This Viewpoint argues that the current model of payment coverage decisions for oncology drugs based on third-party drug compendia is outdated and should be abandoned for a new approach.
This Viewpoint describes 6 pilot programs from the Centers for Medicare & Medicaid Services aimed at lowering Part B drug costs by discussing their application to cancer treatments.
This Viewpoint addresses the benefits and challenges of adopting indication-specific pricing for cancer drugs.
With the first Everolimus for Liver Cancer Evaluation (EVOLVE-1) study, Zhu and coauthors investigated the efficacy of everolimus in patients with advanced hepatocellular carcinoma for whom sorafenib treatment failed. This randomized, double-blind, phase 3 study was conducted among 546 adults with Barcelona Clinic Liver Cancer stage B or C hepatocellular carcinoma and Child-Pugh A liver function.
J.-K. Lee and coauthors performed a systematic review and meta-analysis to determine the association between survival and first-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors vs chemotherapy among patients with advanced non–small cell lung cancer with wild-type EGFR.